Related content

Ifosfamide/Mesna as Salvage Therapy in Platinum Pretreated Ovarian Cancer Patients—Long-Term Results of a Phase II Study

By Baur Martina   Fazeny-Doerner B.   Hudec M.   Sevelda P.   Salzer H.   Dittrich Christian  

Cancer Investigation, Vol. 24, Iss. 1, 2006-03 ,pp. : 22-27

Informa Healthcare

Access to resources Recommend Favorite

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets

By Ramondetta L.M.   Burke T.W.   Jhingran A.   Schmandt R.   Bevers M.W.   Wolf J.K.   Levenback C.F.   Broaddus R.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 529-536

Elsevier

Access to resources Recommend Favorite

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP

By Dincol Dilek   Buyukcelik Abdullah   Dogan Mutlu   Akbulut Hakan   Samur Mustafa   Demirkazik Ahmet   Senler Filiz   Onur Handan   Icli Fikri  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 942-945

Humana Press, Inc

Access to resources Recommend Favorite

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

By  

Oncology Letters, Vol. 8, Iss. 6, 2014-01 ,pp. : 2485-2488

Spandidos Publications

Access to resources Recommend Favorite